Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast.

Targeted oncology - 1 Jan 2023

John Thomas, Majem Margarita, Legg Diane, Goldman Jonathan

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors
Share to Erlotinib Hydrochloride
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Quality of Life

Source

Open in PubMed Open full text

Identifiers

PMID: 36534268
DOI: 10.1007/s11523-022-00927-5
PMCID: PMC9928809

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast.PMID 36534268Read ↗

Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial.Semantic proximity Read ↗

Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial.Semantic proximity Read ↗

Efficacy of erlotinib and its effects on the quality of life of older patients with epidermal growth factor receptor-mutant non-small cell lung cancer: A prospective, multicenter, dose-modification study.Semantic proximity Read ↗

10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient.Semantic proximity Read ↗

Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study.Semantic proximity Read ↗

Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy.Semantic proximity Read ↗

Short-and long-term outcomes of video-assisted thoracoscopic lobectomy in elderly patients with non-small-cell lung cancerSemantic proximity Read ↗

The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report.Semantic proximity Read ↗

Health-Related Quality of Life and its Determinants in Patients with Malignant Brain Tumors: A prospective longitudinal studySemantic proximity Read ↗

Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trialSemantic proximity Read ↗

Perioperative EGFR-Targeted Therapy in Resectable EGFR-Mutated NSCLC: A Narrative Review from Drug Design to Pain-Informed MRD-Guided Care.Semantic proximity Read ↗

The Impact of Comorbidities, Neutrophil-to-lymphocyte Ratio, and Adverse Events on Quality of Life in Lung Cancer Patients Receiving EGFR-TKI TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.